Ovid.com  |  Login  |  Technical Support  

Advanced Search
Ovid News
Learn about Ovid’s new research content and products.
Ovid Events
Check out where Ovid is across the globe at industry conferences and events worldwide.
Are you affiliated with a leading medical or academic institution?
If so, send your librarian an email recommending titles you’ve found valuable for research at your institution.
Home About Products & Services Contact Us btn_contact1
Clinical Chemistry and Laboratory Medicine

March 2009, 47:3 > Phenotyping of congenic dipeptidyl...
< Previous  |   Next >
Fulltext  |  PDF (301 K)
Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions 1.


Clinical Chemistry & Laboratory Medicine. 47(3):275-287, March 2009.
Frerker, Nadine 1; Raber, Kerstin 1,2; Bode, Felix 1; Skripuletz, Thomas 1; Nave, Heike 1; Klemann, Christian 1; Pabst, Reinhard 1; Stephan, Michael 1,3; Schade, Jutta 1; Brabant, Georg 4; Wedekind, Dirk 5; Jacobs, Roland 6; Jorns, Anne 7; Forssmann, Ulf 8; Straub, Rainer H. 9; Johannes, Sigrid 10; Hoffmann, Torsten 11; Wagner, Leona 11; Demuth, Hans-Ulrich 11; von Horsten, Stephan 1,2,*

Background: Treatment of diabetes type 2 using chronic pharmacological inhibition of dipeptidyl peptidase 4 (DP4) still requires an in-depth analysis of models for chronic DP4 deficiency, because adverse reactions induced by some DP4 inhibitors have been described.

Methods: In the present study, a novel congenic rat model of DP4 deficiency on a "DP4-high" DA rat genetic background was generated (DA.F344-Dpp4m/SvH rats) and comprehensively phenotyped.

Results: Similar to chronic pharmacological inhibition of DP4, DP4 deficient rats exhibited a phenotype involving reduced diet-induced body weight gain and improved glucose tolerance associated with increased levels of glucagon-like peptide-1 (GLP-1) and bound leptin as well as decreased aminotransferases and triglycerides. Additionally, DA.F344-Dpp4m/SvH rats showed anxiolytic-like and reduced stress-like responses, a phenomenon presently not targeted by DP4 inhibitors. However, several immune alterations, such as differential leukocyte subset composition at baseline, blunted natural killer cell and T-cell functions, and altered cytokine levels were observed.

Conclusions: While this animal model confirms a critical role of DP4 in GLP-1-dependent glucose regulation, genetically induced chronic DP4 deficiency apparently also affects stress-regulatory and immune-regulatory systems, indicating that the use of chronic DP4 inhibitors might have the potential to interfere with central nervous system and immune functions in vivo.

Copyright (C) 2009 Walter de Gruyter